Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Interneuron Pharmaceutic. (NasdaqNM:IPIC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
One Ledgemont Center, 99 Hayden Avenue
Lexington, MA 02421
Phone: (781) 861-8444
Fax: (781) 861-3830
Email: corpcomm@interneuron.com
Employees (last reported count): 18
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 38%
·Over the last 6 months:
 · 10 insider sells; 548.0K shares
  (3.2% of insider shares)
·Institutional: 35% (57% of float)
(73 institutions)
·Net Inst. Buying: 9.41M shares (+38.13%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Interneuron Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of a diversified portfolio of product candidates, including multiple compounds in late-stage clinical development. The Company is currently developing, or has certain rights to, five compounds in clinical development. These compounds are pagoclone for panic and generalized anxiety disorders, trospium for overactive bladder, IP 501 for cirrhosis of the liver, citicoline for ischemic stroke, and PRO 2000 for the prevention of sexually transmitted diseases and human immunodeficiency virus (HIV) infection. In addition, the Company has other compounds in earlier stages of development, including pituitary adenylate cyclase activating polypeptide (PACAP) for respiratory diseases, diabetes, stroke and other neurodegenerative diseases.
More from Market Guide: Expanded Business Description

Financial Summary
IPIC is a biopharmaceutical company engaged in the development and commercialization of a portfolio of products primarily for neurological and behavioral diseases. For the nine months ended 6/30/01, revenues decreased 96% to $932 thousand. Net income decreased 96% to $558 thousand. Revenues reflect the absence of license fees from Pfizer and Takeda. Net income also reflects increased S/G/A expenses as a percentage of revenues.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Glenn Cooper, M.D., 48
Chairman, Pres, CEO
$901K--  
Michael Rogers, 40
Exec. VP, CFO and Treasurer
637K--  
Mark Butler, 54
Exec. VP, CAO and Gen. Counsel
628K$149K
Bobby Sandage, Jr., Ph.D., 47
Exec. VP, R&D and CSO
624K--  
Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:IPICAs of 31-Aug-2001
Price and Volume
52-Week Low
on 6-Dec-2000
$1.156
Recent Price$5.00 
52-Week High
on 25-June-2001
$10.00 
Beta1.71 
Daily Volume (3-month avg)423.4K
Daily Volume (10-day avg)114.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+100.0%
52-Week Change
relative to S&P500
+168.3%
Share-Related Items
Market Capitalization$216.3M
Shares Outstanding43.3M
Float26.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.61 
Earnings (ttm)$0.11 
Earnings (mrq)$0.09 
Sales (ttm)$0.11 
Cash (mrq)$0.76 
Valuation Ratios
Price/Book (mrq)8.13 
Price/Earnings (ttm)45.45 
Price/Sales (ttm)45.16 
Income Statements
Sales (ttm)$4.93M
EBITDA (ttm)$3.46M
Income available to common (ttm)$5.36M
Profitability
Profit Margin (ttm)108.1%
Operating Margin (ttm)67.6%
Fiscal Year
Fiscal Year EndsSep 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)12.60%
Return on Equity (ttm)23.80%
Financial Strength
Current Ratio (mrq)4.01 
Debt/Equity (mrq)0 
Total Cash (mrq)$32.9M
Short Interest
As of 8-Aug-2001
Shares Short607.0K
Percent of Float2.3%
Shares Short
(Prior Month)
879.0K
Short Ratio3.10 
Daily Volume196.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.